Koers Cellectar Biosciences Inc Nasdaq
Aandelen
US15117F2039
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | - | Omzet 2025 * | 54,14 mln. 50,55 mln. | Marktkapitalisatie | 89,62 mln. 83,67 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -56 mln. -52,28 mln. | Nettowinst (verlies) 2025 * | -24 mln. -22,41 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,66 x |
K/w-verhouding 2024 * |
-1,52
x | K/w-verhouding 2025 * |
-3,89
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 90,91% |
Recentste transcriptie over Cellectar Biosciences Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
James Caruso
CEO | Chief Executive Officer | 65 | 15-06-15 |
Chad Kolean
DFI | Director of Finance/CFO | 59 | 28-05-14 |
Andrei Shustov
CTO | Chief Tech/Sci/R&D Officer | - | 15-02-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 73 | 07-04-17 |
Douglas Swirsky
CHM | Chairman | 54 | 07-04-17 |
John Neis
BRD | Director/Board Member | 68 | 01-02-08 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+55,32% | 815 mld. | |
-6,75% | 352 mld. | |
+13,56% | 314 mld. | |
+10,68% | 303 mld. | |
+16,57% | 242 mld. | |
+2,04% | 224 mld. | |
+13,31% | 218 mld. | |
+8,48% | 168 mld. | |
-2,81% | 159 mld. |
- Beurs
- Aandelen
- Koers CLRB
- Koers